WebApr 10, 2024 · The current study focuses on the Pd (II) and Pt (II) trinuclear chelates with spermidine (Pd 3 Spd 2 and Pt 3 Spd 2) and aims to evaluate its putative anticancer activity towards cisplatin-resistant TNBC cells (MDA-MB-231/R), as compared to cisplatin-sensitive TNBC (MDA-MB-231), by assessing the (i) antiproliferative activity, (ii) … Cisplatin interferes with DNA replication, which kills the fastest proliferating cells, which in theory are cancerous. Following administration, one chloride ion is slowly displaced by water to give the aquo complex cis-[PtCl(NH3)2(H2O)] , in a process termed aquation. Dissociation of the chloride is favored inside the cell because the intracellular chloride concentration is only 3–20% of the approxi…
Cisplatin: The first metal based anticancer drug - PubMed
National Center for Biotechnology Information www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov WebApr 29, 2024 · In order to overcome cisplatin-resistance, seven cyclometalated ruthenium ( II) complexes were synthesized with a varying degree of fluorine substitution, for use as anticancer agents. A cytotoxicity assay testified that the complexes possessed a more cytotoxic effect than cisplatin towards the cisplatin-resistant cell line A549R. greenleaf flowlogic sign in
Cisplatin (Anti-cancer Drug) - SlideShare
WebMar 15, 2011 · Numerous mechanisms of cisplatin resistance were described including changes in cellular uptake, drug efflux, increased detoxification, inhibition of apoptosis and increased DNA repair. To minimize cisplatin resistance, combinatorial therapies were developed and have proven more effective to defeat cancers. WebCisplatin exerts anticancer activity via multiple mechanisms but its most acceptable mechanism involves generation of DNA lesions by interacting with purine bases on DNA … fly from mia to cnf